Abstract
Background Context
Purpose
Study Design
Patient Sample
Outcome Measures
Methods
Results
Conclusions
Keywords
Introduction
Methods
Study design and participant recruitment procedures
Primary outcome measure
Potential prognostic factors
Variable set | Domain | Measure |
---|---|---|
1 | Duration of pain | Current episode of leg pain: Less than 6 wk, between 6 and 12 wk, more than 3 mo |
2 | Pain intensity | Taking the highest of either back or leg pain using the mean of three 0 to 10 numerical rating scales for “least,” “usual,” and “current” pain over the previous 2 wk [22] |
3 | Neuropathic pain features | Using the Leeds Assessment Neuropathic Symptoms and Signs (S-LANSS); with a score of 12 or more indicating possible neuropathic pain [23] |
4 | Psychological perceptions | Pain self-efficacy: Measured with the Pain Self-Efficacy Questionnaire (PSEQ); with scores from 0 to 60; higher scores reflect stronger self-efficacy beliefs [24] Identity; Symptom attribution to the condition [25] from a list of seven potential symptoms: back pain, leg pain, unable to sit comfortably, fatigue, stiff joints, sleep difficulties, loss of strength. The score is the sum of symptoms experienced. The list of the seven potential symptoms was chosen by the research team.Timeline; illness/condition duration: “My back and/or leg problem will last for a long time” Personal control: How much influence a patient has over illness/condition; “There is a lot which I can do to control my back and/or leg symptoms” Depression: Measured using the Hospital Anxiety and Depression scale (HADs); with scores from 0 to 21, higher scores indicate higher levels of depressive symptoms [26] |
5 | Clinical examination | Pins and needles or numbness in leg(s) as reported by the patient. Leg pain increased by coughing/laughing/straining. Worse pain, either in low back or leg. Neurological examination variables: –Myotomal strength † : Defined as normal (5 on Oxford scale)/abnormal (0, 1, 2, 3, or 4 on Oxford scale)Muscle strength tested according to the Oxford scale, where 0, no movement; 1, flicker of movement; 2, through full range actively with gravity counterbalanced; 3, through full range actively against gravity; 4, through full range actively against some resistance; 5, through full range actively against strong resistance. –Reflex (tendon): Defined as normal, slightly reduced, significantly reduced/absent –Sensation (in leg(s)) Defined as normal/abnormal –Neural tension test findings: Defined as abnormal if any neural tension test is abnormal (ie, straight leg raise, femoral stretch, slump) |
6 | Imaging (MRI) examination | MRI findings: Defined as normal when no evidence of nerve root compression correlating with clinical symptoms, or indicative of nerve root compression if there was evidence of clear or possible nerve root compression for any reason. All MRIs were scored by the same experienced consultant radiologist who had no knowledge of the specific patient presentation other than “LBP with leg pain.” |
Treatment pathways
Data analysis
Overall prognosis
Analysis of prognostic factors
Assessment of nonresponse
Results
Study sample

All participants n=609 | Sciatica subgroup n=452 | Referred leg pain n=157 | |
---|---|---|---|
Sociodemographics (Denominator) | |||
Age (y) (609), mean (SD) | 50.2 (13.9) | 50.4 (14.0) | 49.4 (13.7) |
Gender (609), Female | 381 (62.6) | 276 (61.1) | 105 (66.9) |
BMI (609), mean (SD) | 29.9 (7.0) | 29.9 (6.3) | 30.0 (8.7) |
Current smoker (609) | 194 (31.9) | 151 (33.4) | 43 (27.4) |
Comorbidities (609) | |||
None | 371 (60.9) | 277 (61.3) | 94 (59.9) |
One other health problem | 158 (25.9) | 122 (27.0) | 36 (22.9) |
Two or more other health problems | 80 (13.1) | 53 (11.7) | 27 (17.2) |
Pain and function | |||
RMDQ disability score (0–23) (609), mean (SD) | 12.7 (5.7) | 12.9 (5.7) | 12.0 (5.7) |
Back pain intensity (mean of 3 NRS) (609), mean (SD) | 5.6 (2.2) | 5.6 (2.2) | 5.4 (2.1) |
Leg pain intensity (mean of 3 NRS) (608), mean (SD) | 5.2 (2.4) | 5.6 (2.3) | 4.1 (2.3) |
Duration of symptoms | |||
Back pain (607) | |||
<6 wk | 218 (35.9) | 174 (38.6) | 44 (28.2) |
6–12 wk | 126 (20.8) | 96 (21.3) | 30 (19.2) |
3–6 mo | 92 (15.2) | 75 (16.6) | 17 (10.9) |
Over 6 mo | 171 (28.2) | 106 (23.5) | 65 (41.7) |
Leg pain (583) | |||
<6 wk | 251 (43.1) | 192 (44.2) | 59 (39.6) |
6–12 wk | 120 (20.6) | 94 (21.7) | 26 (17.5) |
3–6 mo | 84(14.4) | 62 (14.3) | 22 (14.8) |
Over 6 mo | 128 (22.0) | 86 (19.8) | 42 (28.0) |
Leg pain is worse (609) | 280 (46.0) | 252 (55.8) | 28 (17.8) |
S-LANSS (possible neuropathic pain) (607) | 332 (54.8) | 232(51.6) | 61 (39.0) |
Psychological measures and perceptions | |||
HADs depression subscale (continuous score) (609), mean (SD) | 6.4 (4.0) | 6.3 (4.0) | 6.4 (4.0) |
HADs depression subscale: categorized (609) | |||
Normal (0–7) | 392 (64.4) | 295 (65.3) | 97 (61.8) |
Possible case (8–10) | 119 (19.5) | 82 (18.1) | 37 (23.4) |
Probable case (≥11) | 98 (16.1) | 75 (16.6) | 23 (14.7) |
Pain self-efficacy score (593), mean (SD) | 34.1 (14.6) | 33.3 (14.7) | 36.6 (13.9) |
Illness perception | |||
–Identity score (609), mean (SD) | 5.9 (1.3) | 5.9 (1.3) | 5.9 (1.2) |
–Timeline (“back/leg pain will last forever” [agree/strongly agree]) (609) | 345 (56.7) | 249 (55.1) | 96 (61.2) |
–Personal control (“what I do can determine whether back/leg pain gets better/worse” [agree/strongly agree]) (605) | 367 (60.7) | 277 (61.8) | 90 (57.3) |
Clinical assessment | |||
Pins and needles and/or numbness (patient reports having these symptoms) (609) | 382 (62.7) | 316 (69.9) | 66 (42.0) |
Cough, sneeze or strain (patient reports increased leg pain with cough/sneeze/strain) (609) | 129 (21.2) | 120 (26.6) | 9 (5.7) |
Leg pain is worse than back pain (patient report) (609) | 280 (46.0) | 252 (55.8) | 28 (17.8) |
Myotomal change (as per Oxford scale) (608) | |||
5/5 (None) | 503 (82.7) | 347 (76.8) | 156 (100) |
4/5 | 92 (15.1) | 92 (20.4) | 0 (0.0) |
0/5 or 1/5 or 2/5 or 3/5 | 13 (2.1) | 13 (2.9) | 0 (0.0) |
Reflex change (at ankle or patella) (609) | |||
None | 490 (80.5) | 341 (75.4) | 149 (94.9) |
Slightly reduced | 30 (4.9) | 30 (6.6) | 0 (0.0) |
Significantly reduced | 22 (3.6) | 19 (4.2) | 3 (1.9) |
Absent | 67 (11.0) | 62 (13.7) | 5 (3.2) |
Sensory change (as examined using a pin) (609) | |||
None | 356 (58.5) | 226 (50.0) | 130 (82.8) |
Reduced pin/prick | 201 (33.0) | 175 (38.7) | 26 (16.6) |
Loss to pin/prick | 52 (8.5) | 51 (11.3) | 1 (0.6) |
Neural tension test positive (any) (609) | 335 (55.0) | 324 (71.7) | 11 (7.0) |
MRI (554) | |||
Findings of nerve root compression | 297 (53.6) | 252 (60.7) | 45 (32.4) |
Prognosis of low back-related leg pain and sciatica
Prognostic factors associated with long-term changes in disability
Improved vs. not improved: reference category in parentheses | All participants | Sciatica subgroup | ||
---|---|---|---|---|
4 mo (n=402) | 12 mo (n=450) | 4 mo (n=308) | 12 mo (n=338) | |
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Pain variables (Sets 1, 2, 3) | ||||
Duration of leg pain (<6 wk) | ||||
6–12 wk | 0.73 (0.28–1.93) | 1.02 (0.39–2.61) | 0.55 (0.17–1.79) | 1.10 (0.35–3.46) |
Over 3 mo | 0.16 (0.07–0.38) | 0.23 (0.10–0.52) | 0.09 (0.03–0.29) | 0.19 (0.07–0.56) |
Pain intensity (cont) | 0.66 (0.55–0.79) | 0.74 (0.63–0.89) | 0.62 (0.49–0.79) | 0.73 (0.58–0.91) |
S-LANSS: possible neuropathic pain (No) | 0.31 (0.14–0.65) | 0.46 (0.23–0.93) | 0.26 (0.10–0.66) | 0.37 (0.15–0.92) |
Psychological measures and perceptions (Set 4) | ||||
Pain self-efficacy | 1.05 (1.02–1.08) | 1.04 (1.01–1.06) | 1.04 (1.01–1.08) | 1.04 (1.01–1.08) |
Illness perception | ||||
–Identity | 0.54 (0.40–0.73) | 0.52 (0.38–0.69) | 0.48 (0.33–0.69) | 0.48 (0.33–0.70) |
–Timeline † Timeline and personal control are measured on a Likert scale: Strongly disagree—Disagree—Neither agree or disagree—Agree—Strongly agree. For the purposes of the analysis, it was dichotomized (agree [agree, strongly agree] vs. disagree [strongly disagree, disagree, neither agree, or disagree]). The reference for the analysis is “Strongly disagree/disagree/neither.” | 0.33 (0.16–0.69) | 0.20 (0.09–0.41) | 0.29 (0.11–0.73) | 0.12 (0.05–0.33) |
–Personal control † Timeline and personal control are measured on a Likert scale: Strongly disagree—Disagree—Neither agree or disagree—Agree—Strongly agree. For the purposes of the analysis, it was dichotomized (agree [agree, strongly agree] vs. disagree [strongly disagree, disagree, neither agree, or disagree]). The reference for the analysis is “Strongly disagree/disagree/neither.” | 1.40 (0.66–2.96) | 1.55 (0.76–3.18) | 1.37 (0.54–3.51) | 1.61 (0.65–4.00) |
HADs depression (cont) | 0.82 (0.75–0.91) | 0.86 (0.78–0.94) | 0.82 (0.73–0.93) | 0.82 (0.73–0.93) |
Clinical assessment and imaging (Set 5, 6) | ||||
Reporting pins and needles and/or numbness (No) | 0.47 (0.22–1.02) | 0.86 (0.42–1.76) | 0.76 (0.30–1.93) | 1.45 (0.59–3.58) |
Increased leg pain with cough/sneeze/strain (No) | 0.74 (0.29–1.87) | 0.82 (0.34–1.94) | 0.94 (0.32–2.79) | 0.89 (0.32–2.47) |
What is worse (Back pain) | 1.58 (0⋅76–3.27) | 1.13 (0.56–2.27) | 3.15 (1.22–8.10) | 1.95 (0.79–4.78) |
Myotomes (No weakness [normal]) | 1.66 (0.64–4.29) | 2.62 (1.02–6.69) | 2.08 (0.70–6.16) | 3.22 (1.10–9.46) |
Reflex (Normal) | ||||
Slightly reduced | 0.19 (0.03–1.17) | 0.72 (0.13–3.91) | 0.18 (0.02–1.32) | 0.69 (0.12–4.59) |
Absent or significantly reduced | 0.58 (0.20–1.68) | 0.46 (0.17–1.30) | 0.67 (0.19–2.32) | 0.43 (0.13–1.44) |
Sensation (Normal) | 0.54 (0.25–1.13) | 0.57 (0.28–1.17) | 0.61 (0.24–1.53) | 0.46 (0.19–1.12) |
Neural tension test (Normal) | 1.04 (0.50–2.16) | 0.92 (0.46–1.85) | 1.58 (0.59–4.23) | 1.02 (0.39–2.68) |
MRI finding: Nerve root compression (No) | 1.07 (0.50–2.29) | 1.06 (0.51–2.18) | 1.00 (0.37–2.68) | 1.08 (0.41–2.82) |
Variables in the model (Reference category) | 4 mo (n=402) | 12 mo (n=450) | ||||
---|---|---|---|---|---|---|
Adjusted for all the variables in the model | Adjusted for the variables in the model and demographics | Adjusted for all the variables in the model, demographics, and care pathways | Adjusted for only variables in the model | Adjusted for the variables in the model and demographics | Adjusted for all the variables in the model, demographics, and care pathways | |
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Model 1 | ||||||
Duration of leg pain (<6 wk) | ||||||
6–12 wk | 0.73 (0.28–1.93) | 0.67 (0.26–1.73) | 0.81 (0.31–2.12) | 1.02 (0.39–2.61) | 0.87 (0.35–2.19) | 0.92 (0.3–2.31) |
Over 3 mo | 0.16 (0.07–0.38) | 0.22 (0.09–0.51) | 0.26 (0.11–0.61) | 0.23 (0.10–0.52) | 0.29 (0.13–0.63) | 0.30 (0.13–0.66) |
Model 2 | ||||||
Pain intensity (cont) | 0.66 (0.55–0.79) | 0.71 (0.60–0.86) | 0.76 (0.63–0.91) | 0.75 (0.63–0.89) | 0.82 (0.69–0.97) | 0.84 (0.71–0.99) |
Model 3 | ||||||
S-LANSS: possible neuropathic origin (No) | 0.31 (0.14–0.65) | 0.37 (0.18–0.77) | 0.44 (0.21–0.91) | 0.46 (0.23–0.93) | 0.60 (0.30–1.19) | 0.65 (0.33–1.29) |
Model 4 | ||||||
Pain self-efficacy | 1.03 (0.99–1.06) | 1.02 (0.99–1.06) | 1.02 (0.99–1.05) | 1.00 (0.97–1.03) | 0.99 (0.96–1.02) | 0.99 (0.96–1.03) |
Illness perception | ||||||
–Identity | 0.64 (0.46–0.88) | 0.74 (0.54–1.00) | 0.77 (0.56–1.05) | 0.58 (0.42–0.80) | 0.67 (0.49–0.91) | 0.68 (0.50–0.93) |
–Timeline | 0.52 (0.25–1.11) | 0.49 (0.23–1.01) | 0.55 (0.26–1.16) | 0.31 (0.15–0.65) | 0.28 (0.13–0.59) | 0.29 (0.14–0.60) |
–Personal control | 1.49 (0.69–3.19) | 1.57 (0.75–3.27) | 1.48 (0.70–3.13) | 1.52 (0.73–3.17) | 1.61 (0.79–3.30) | 1.60 (0.78–3.29) |
HAD depression (cont) | 0.95 (0.84–1.08) | 0.96 (0.84–1.08) | 0.96 (0.84–1.09) | 0.96 (0.85–1.08) | 0.96 (0.85–1.08) | 0.96 (0.85–1.09) |
Model 5 | ||||||
Reporting pins and needles and/or numbness (No) | 0.57 (0.26–1.26) | 0.61 (0.28–1.33) | 0.66 (0.30–1.44) | 1.02 (0.48–2.17) | 1.23 (0.59–2.57) | 1.32 (0.63–2.76) |
Increased leg pain with cough/sneeze/strain (No) | 0.78 (0.29–2.11) | 0.62 (0.24–1.64) | 0.82 (0.30–2.19) | 0.83 (0.33–2.09) | 0.71 (0.29–1.74) | 0.77 (0.31–1.88) |
What is worse (Back pain) | 1.65 (0.74–3.68) | 1.74 (0.80–3.78) | 1.72 (0.79–3.74) | 1.18 (0.55–2.53) | 1.24 (0.60–2.59) | 1.28 (0.61–2.66) |
Myotomes (No weakness [normal]) | 2.61 (0.92–7.41) | 2.69 (0.98–7.40) | 3.47 (1.22–9.82) | 3.92 (1.42–10.83) | 4.10 (1.53–11.00) | 4.56 (1.69–12.33) |
Reflex (Normal) | ||||||
Slightly reduced | 0.14 (0.02–0.91) | 0.16 (0.03–1.00) | 0.16 (0.03–1.01) | 0.52 (0.09–2.95) | 0.57 (0.10–3.07) | 0.58 (0.11–3.11) |
Absent or significantly reduced | 0.53 (0.18–1.58) | 0.47 (0.16–1.35) | 0.53 (0.18–1.54) | 0.41 (0.15–1.17) | 0.35 (0.13–0.98) | 0.38 (0.14–1.05) |
Sensation (Normal) | 0.53 (0.24–1.16) | 0.66 (0.31–1.42) | 0.74 (0.34–1.59) | 0.49 (0.23–1.05) | 0.65 (0.31–1.36) | 0.67 (0.33–1.40) |
Neural tension test (Normal) | 1.04 (0.46–2.36) | 0.95 (0.43–2.09) | 1.01 (0.45–2.25) | 0.88 (0.40–1.96) | 0.75 (0.35–1.63) | 0.80 (0.37–1.73) |
Model 6 | ||||||
MRI finding: Nerve root compression (No) | 1.07 (0.50–2.29) | 0.95 (0.45–2.00) | 1.30 (0.60–2.80) | 1.06 (0.51–2.18) | 0.95 (0.47–1.93) | 1.05 (0.51–2.15) |
Variables in the model (Reference category) | 4 mo (n=308) | 12 mo (338) | ||||
---|---|---|---|---|---|---|
Adjusted for all the variables in the model | Adjusted for the variables in the model and demographics | Adjusted for all the variables in the model, demographics, and care pathways | Adjusted for only variables in the model | Adjusted for the variables in the model and demographics | Adjusted for all the variables in the model, demographics, and care pathways | |
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Model 1 | ||||||
Duration of leg pain (<6 wk) | ||||||
6–12 wk | 0.55 (0.17–1.79) | 0.50 (0.16–1.60) | 0.65 (0.19–2.19) | 1.10 (0.35–3.46) | 0.96 (0.31–2.92) | 1.01 (0.31–3.22) |
Over 3 mo | 0.09 (0.03–0.28) | 0.14 (0.05–0.41) | 0.16 (0.05–0.50) | 0.19 (0.07–0.56) | 0.26 (0.09–0.73) | 0.23 (0.08–0.69) |
Model 2 | ||||||
Pain intensity (cont) | 0.62 (0.49–0.79) | 0.69 (0.54–0.87) | 0.75 (0.59–0.95) | 0.73 (0.58–0.91) | 0.78 (0.63–0.98) | 0.81 (0.64–1.01) |
Model 3 | ||||||
S-LANSS: possible neuropathic pain (No) | 0.26 (0.10–0.66) | 0.32 (0.13–0.81) | 0.37 (0.14–0.96) | 0.37 (0.15–0.92) | 0.50 (0.21–1.19) | 0.52 (0.21–1.26) |
Model 4 | ||||||
Pain self-efficacy | 1.01 (0.97–1.04) | 1.01 (0.97–1.05) | 1.00 (0.9–1.04) | 0.99 (0.96–1.04) | 0.99 (0.96–1.04) | 0.99 (0.95–1.03) |
Illness perception | ||||||
–Identity | 0.54 (0.36–0.80) | 0.63 (0.43–0.91) | 0.65 (0.44–0.96) | 0.56 (0.38–0.83) | 0.64 (0.44–0.94) | 0.64 (0.43–0.95) |
–Timeline | 0.48 (0.19–1.22) | 0.49 (0.20–1.21) | 0.58 (0.22–1.51) | 0.20 (0.08–0.53) | 0.22 (0.08–0.55) | 0.21 (0.08–0.54) |
–Personal control | 1.53 (0.59–3.92) | 1.62 (0.65–4.02) | 1.46 (0.56–3.82) | 1.43 (0.57–3.62) | 1.50 (0.62–3.63) | 1.51 (0.60–3.81) |
HADs depression (cont) | 0.94 (0.80–1.10) | 0.94 (0.80–1.10) | 0.94 (0.80–1.11) | 0.93 (0.80–1.08) | 0.93 (0.81–1.08) | 0.93 (0.78–1.09) |
Model 5 | ||||||
Reporting pins and needles and/or numbness (No) | 0.47 (0.16–1.34) | 0.57 (0.20–1.60) | 0.62 (0.21–1.84) | 0.93 (0.43–2.54) | 1.20 (0.45–3.19) | 1.37 (0.50–3.74) |
Increased leg pain with cough/sneeze/strain (No) | 0.87 (0.28–2.77) | 0.56 (0.18–1.74) | 0.74 (0.23–2.45) | 0.83 (0.29–2.43) | 0.66 (0.23–1.91) | 0.68 (0.23–2.00) |
What is worse (Back pain) | 3.00 (1.09–8.25) | 3.07 (1.15–8.21) | 3.10 (1.12–8.62) | 2.01 (0.77–5.26) | 1.98 (0.78–5.00) | 2.12 (0.85–5.73) |
Myotomes (No weakness [normal]) | 2.75 (0.86–8.77) | 2.92 (0.94–9.09) | 4.31 (1.27–14.63) | 4.57 (1.45–14.40) | 4.57 (1.51–13.82) | 5.62 (1.76–17.92) |
Reflex (Normal) | ||||||
Slightly reduced | 0.11 (0.01–0.92) | 0.12 (0.01–0.99) | 0.12 (0.01–1.07) | 0.46 (0.07–3.19) | 0.51 (0.08–3.34) | 0.56 (0.08–3.79) |
Absent or significantly reduced | 0.56(0.16–2.01) | 0.45 (0.13–1.58) | 0.48 (0.13–1.83) | 0.35 (0.10–1.21) | 0.30 (0.09–1.02) | 0.35 (0.10–1.20) |
Sensation (Normal) | 0.63 (0.24–1.65) | 0.82 (0.32–2.07) | 1.03 (0.39–2.72) | 0.40 (0.16–1.03) | 0.53 (0.22–1.30) | 0.56 (0.23–1.41) |
Neural tension test (Normal (negative) | 1.22 (0.43–3.46) | 1.13 (0.41–3.12) | 1.28 (0.44–3.74) | 0.84 (0.30–2.35) | 0.68 (0.25–1.87) | 0.81 (0.29–2.27) |
Model 6 | ||||||
MRI finding: Nerve root compression (No) | 1.00 (0.37–2.68) | 0.71 (0.27–1.88) | 1.08 (0.38–3.05) | 1.08 (0.42–2.82) | 0.82 (0.32–2.09) | 0.89 (0.33–2.39) |
Independent prognostic factors associated with long-term changes in disability
Variables in the final model (Reference category) | 4 mo | 12 mo | ||||
---|---|---|---|---|---|---|
Adjusted for all the variables in the final model | Adjusted for the variables in the model and demographics | Adjusted for all the variables in the model, demographics, and care pathways | Adjusted for all the variables in the final model | Adjusted for the variables in the model and demographics | Adjusted for all the variables in the model, demographics, and care pathways | |
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Whole group | ||||||
Duration of leg pain (>6 wk) | ||||||
6–12 wk | 0.79 (0.30–2.10) | 0.75 (0.29–1.94) | 0.85 (0.32–2.24) | 1.11 (0.43–2.84) | 1.03 (0.41–2.56) | 1.04 (0.41–2.62) |
Over 3 mo | 0.23 (0.10–0.55) | 0.28 (0.12–0.64) | 0.31 (0.13–0.72) | 0.36 (0.16–0.79) | 0.42 (0.19–0.92) | 0.41 (0.19–0.90) |
–Timeline | — | — | — | 0.31 (0.15–0.64) | 0.27 (0.13–0.56) | 0.27 (0.13–0.57) |
Pain intensity (cont) | 0.75 (0.63–0.91) | 0.80 (0.67–0.96) | 0.81 (0.67–0.97) | — | — | — |
–Identity | 0.66 (0.49–0.89) | 0.73 (0.54–0.97) | 0.74 (0.54–0.99) | 0.59 (0.44–0.79) | 0.69 (0.52–0.91) | 0.70 (0.53–0.93) |
Sciatica subgroup | ||||||
Duration of leg pain (>6 wk) | ||||||
6–12 wk | 0.58 (0.18–1.86) | 0.56 (0.18–1.76) | 0.66 (0.20–2.20) | 1.30 (0.41–4.10) | 1.27 (0.41–3.82) | 1.29 (0.40–4.19) |
Over 3 mo | 0.15 (0.05–0.46) | 0.19 (0.07–0.57) | 0.20 (0.06–0.63) | 0.31 (0.11–0.88) | 0.41 (0.15–1.11) | 0.34 (0.11–1.01) |
–Timeline | — | — | — | 0.21 (0.08–0.55) | 0.22 (0.09–0.56) | 0.21 (0.08–0.56) |
Pain intensity (cont) | 0.70 (0.54–0.89) | 0.75 (0.59–0.96) | 0.79 (0.62–1.02) | — | — | — |
–Identity | 0.63 (0.43–0.90) | 0.69 (0.49–0.99) | 0.74 (0.51–1.07) | 0.57 (0.39–0.81) | 0.64 (0.45–0.91) | 0.65 (0.45–0.94) |
What is worse (back pain) | 3.47 (1.32–9.11) | 3.15 (1.22–8.12) | 3.37 (1.25–9.08) | — | — | — |
Discussion
Strengths and limitations
Suggestions for further research
Conclusions
Acknowledgments
Supplementary material
- Table S1
Baseline characteristics of participants followed up and lost to follow-up at 4 and 12 months.
- Table S2
Multivariable associations between baseline characteristics and improvement in the RMDQ for the subsample of participants with sciatica and corroborative MRI findings of nerve root compression (n=252), combining all the six preselected set of variables.
References
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010.Lancet. 2012; 380: 216-396
- Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases.Br J Gen Pract. 2007; 57: 7-14
- Clinical outcomes among low back pain consulters with referred leg pain in primary care.Spine. 2011; 36: 2168-2175
- The impact of low back-related leg pain on outcomes as compared with low back pain alone: a systematic review of the literature.Clin J Pain. 2013; 29: 644-654
- The prognosis of acute and persistent low-back pain: a meta-analysis.CMAJ. 2012; 184: E613-E624https://doi.org/10.1503/cmaj.111271
- Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society.Spine. 2009; 34: 1066-1077
- Low back pain research—future directions.Best Pract Res Clin Rheumatol. 2013; 27: 6997-7008
- Prognostic factors for recovery in chronic nonspecific low back pain: a systematic review.Phys Ther. 2012; 92: 1093-1108
- Stratified models of care.Best Pract Res Clin Rheumatol. 2013; 27: 649-661
- Prognostic factors in non-surgically treated sciatica: a systematic review.BMC Musculoskelet Disord. 2011; 12: 208
- Systematic review of prognostic factors predicting outcome in non-surgically treated patients with sciatica.Eur J Pain. 2013; 17: 1126-1137
- Clinical examination findings as prognostic factors in low back pain: a systematic review of the literature.Chiropr Man Therap. 2015; 23: 13
- Prognostic factors for non-success in patients with sciatica and disc herniation.BMC Musculoskelet Disord. 2012; 13: 183
- Outcome prediction in chronic unilateral lumbar radiculopathy: prospective cohort study.BMC Musculoskelet Disord. 2015; 16: 17
- Comparative clinical effectiveness of management strategies for sciatica: systematic review and network meta-analyses.Spine J. 2015; 15: 1461-1477
- Nonoperative treatment for lumbosacral radiculopathy: what factors predict treatment failure?.Clin Orthop Relat Res. 2015; 473: 1931-1939
- Clinical course, characteristics and prognostic indicators in patients presenting with back and leg pain in primary care. The ATLAS study protocol.BMC Musculoskelet Disord. 2012; 13: 4
- ATLAS study research team. Characteristics of patients with low back and leg pain seeking treatment in primary care: baseline results from the ATLAS cohort study.BMC Musculoskelet Disord. 2015; 16: 332
- Reliability among clinicians diagnosing low back-related leg pain.Eur Spine J. 2016; 25: 2734-2740
- Assessing health-related quality of life in patients with sciatica.Spine. 1995; 20: 1899-1908
- A minimal clinically important difference was derived for the Roland-Morris Disability Questionnaire for low back pain.J Clin Epidemiol. 2006; 59: 45-52
- Recall of medication use, self-care activities and pain intensity: a comparison of daily diaries and self-report questionnaires among low back pain patients.Prim Health Care Res Dev. 2010; 11: 93-102
- The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research.J Pain. 2005; 6: 149-158
- The pain self-efficacy questionnaire: taking pain into account.Eur J Pain. 2007; 11: 153-163
- The Revised Illness Perceptions Questionnaire (IPQ-R).Psychol Health. 2002; 17: 1-16
- The hospital anxiety and depression scale.Acta Psychiatr Scand. 1983; 67: 361-370
- A simulation study of the number of events per variable in logistic regression analysis.J Clin Epidemiol. 1996; 49: 1373-1379
- Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial.Lancet. 2011; 378: 1560-1571
- Group cognitive behavioural treatment for low-back pain in primary care: a randomised controlled trial and cost-effectiveness analysis.Lancet. 2010; 375: 916-923
- The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam.Spine. 1993; 18: 1433-1438
- The importance of symptom duration in determining prognosis.Pain. 2006; 121: 126-132
- Prognostic factors for musculoskeletal pain in primary care: a systematic review.Br J Gen Pract. 2007; 57: 655-661
- Distinctiveness of psychological obstacles to recovery n low back pain patients in primary care.Pain. 2010; 148: 398-406
- Clinical course and prognostic factors in acute low back pain: patients consulting primary care for the first time.Spine. 2005; 30: 976-982
- Unexpected predictor–outcome associations in clinical prediction research: causes and solutions.CMAJ. 2013; 185
- Prediction models in obstetrics: understanding the treatment paradox and potential solutions to the threat it poses.BJOG. 2016; 123: 1060-1064
Article info
Publication history
Footnotes
FDA device/drug status: Not applicable.
Author disclosures: KK: NIHR (Amount not disclosed, paid directly to institution/employer), pertaining to the submitted work; Grant: HTA NIHR (Amount not disclosed, paid directly to institution/employer); Fellowship Support: NIHR (Amount not disclosed, paid directly to institution/employer), outside the submitted work. KMD: Grant: NIHR (Amount not disclosed, paid directly to institution/employer), pertaining to the submitted work; Grant: HTA NIHR (Paid directly to institution/employer); Fellowship Support: Wellcome Trust (Paid directly to institution/employer), outside the submitted work. RO: Nothing to disclose. ML: Grant: NIHR (Paid directly to institution/employer), pertaining to the submitted work; Grant: HTA NIHR (Paid directly to institution/employer), outside the submitted work. DvdW: Grant: NIHR (Paid directly to institution/employer), pertaining to the submitted work; Grant: HTA, NIHR, Medical Research Council (Paid directly to institution/employer), outside the submitted work. EMH: NIHR (Paid directly to institution/employer), pertaining to the submitted work; Grant: HTA NIHR Arthritis Research UK (Paid directly to institution/employer), outside the submitted work.
The disclosure key can be found on the Table of Contents and at www.TheSpineJournalOnline.com.
This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-PG-0707-10131). KMD has been supported by a Wellcome Trust Fellowship. KK is funded by a HEFCE CAT Clinical Senior Lecturer Award. EMH is an NIHR Senior Investigator. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Ethical approval for the ATLAS study was obtained from the South Birmingham Research Ethics Committee (REC Ref. 10/H1207/82).
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy